Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

NCT00454909 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

873

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL: Meningococcal vaccine 134612
BIOLOGICAL: Menactra®

Sponsor

GlaxoSmithKline